Patent ID: 8927025
Filing Date: 2015-01-06
Classification: A61K,A61P

Abstract:
1. An extended release oral dosage form comprising: a matrix, wherein the matrix comprises a gelling polymer in an amount from about 25 to about 45 percent by weight of the dosage form, wherein the matrix does not contain a lipid; and coated granules, wherein the coated granules comprise a granule, comprising: metoprolol or a pharmaceutically acceptable salt or solvate thereof in an amount from about 10 to about 90 percent by weight of the granule, ethyl cellulose in an amount from about 10 to about 30 percent by weight of the granule, and a viscosity modifier in an amount from about 5 to about 30 percent by weight of the granule; and a fat/wax selected from: glycerol fatty esters and waxes and present in an amount from about 0 to about 40 percent by weight of the granule; and a coating on the granule, wherein the coating is present in an amount from about 35 to about 55 percent by weight of the coated granule, and wherein the coating comprises ethyl cellulose in an amount from about 1 to about 50 percent by weight of the coated granule, and an anti-adherent in an amount from about 0 to about 30 percent by weight of the coated granule wherein the gelling polymer in the matrix is selected from hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxyethylcellulose, and carboxymethylcellulose, and wherein the viscosity modifier in the granule is selected from sodium alginate, hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, crosslinked polyacrylic acid, gelatin, pectins, gums, polyethylene oxides, Konjac flour, carrageenan, xanthan gum, or mixtures thereof.